1. BEGIN File 135, NewsRX Weekly Reports, to get updates on biotechnological developments.
2. SELECT terms. Be sure to use proximity connectors when searching a phrase. (N) specifies that terms are next to each other in either order. A number in front of N denotes within so many words. (W) or () stipulates that terms appear next to each other in exact order. A question mark after a word allows for variant word endings.
3. Use a database LIMIT feature to restrict retrieval to a range of years. The colon acts as OR.
|
?b 135
File 135:NewsRx Weekly Reports 1995-2008/Sep W3
(c) 2008 NewsRx
Set Items Description
--- ----- -----------
?select adult(3n)stem(w)cell?
44638 ADULT
30674 STEM
323970 CELL?
S1 2245 ADULT(3N)STEM(W)CELL?
?select S1/2005:2008
2245 S1
692143 PY=2005 : PY=2008
S2 1733 S1/2005:2008
|
4. REMOVE DUPLICATES (RD). It is possible to remove duplicates even in just one database. RD creates a new search set.
5. SORT all the records in the RD set (S3) by “hits” of the search terms. This creates a new search set (S4) sorted by relevancy in descending order. The record with the highest incidence becomes the first record.
|
?rd
S3 1682 RD (unique items)
?sort s3/all/hits
S4 1682 Sort S3/ALL/HITS
|
6. TYPE a few records in Formats 8 and K (KWIC) to see titles, indexing, publication dates, word counts and Key Words in Context.
Notice the amount of “hits” in the first records.
Note: Portions of the records have been omitted. |
?type s4/8,k/1-2
4/8,K/1
DIALOG(R)File 135: NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.
0000230810 (USE FORMAT 7 OR 9 FOR FULLTEXT)
Biotech company developing treatments based on adult stem cells
Word Count:1026
July 18, 2005 (20050718)
DESCRIPTORS: Biotechnology; Biotherapy; Bone Marrow;
Cardiology; Cell Therapy; Clinical Trial; Drug
Development; Heart; Medical Device; Osiris
Therapeutics, Inc.; Pharmaceuticals; Stem Cell
Research; Therapy; Treatment; All News; Consumer
News
SUBJECT HEADING: Stem Cell Research
Biotech company developing treatments based on adult stem cells
...TEXT: nearly 50 Osiris Therapeutics, Inc., employees of the
company continued their work on less controversial adult stem cells.
Thanks to U.S. Food and Drug Administration (FDA) fast-track
designation, Osiris expects to have an adult stem cell-based
therapy on the market by late 2007 to combat potentially fatal
tissue rejection among leukemia patients undergoing bone marrow
transplants. That's one of three adult stem cell-based therapies
Osiris currently has in human trials, to the delight of investors
who muscled...
Another human clinical trial squirts adult stem cells into
damaged knees after surgery to regrow meniscus, restoring the tissue
that acts as a....
4/8,K/2
DIALOG(R)File 135: NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.
0000207858 (USE FORMAT 7 OR 9 FOR FULLTEXT)
Can donor adult stem cells repair muscle damage from heart attack?
Word Count: 962
April 18, 2005 (20050418)
DESCRIPTORS: Bone Marrow; Cardiology; Heart; Johns Hopkins University; Myocardial Infarction; Stem Cell Mobilization; Stem
Cell Research; Transplantation Medicine; All News; Professional News
SUBJECT HEADING: Myocardial Infarction
Can donor adult stem cells repair muscle damage from heart attack?
...TEXT: begun what is believed to be the first clinical trial
in the United States of adult mesenchymal stem cells to repair
muscle damaged by heart attack, or myocardial infarction.
The Phase I study is designed to test the safety of injecting
adult stem cells at varying doses in patients who have recently
suffered a heart attack.
. . . .
|
7. TYPE record(s) of interest in FULL format or Format 9.
Note: A portion of the record has been omitted from this display. |
?t s4/9/1
4/9/1
DIALOG(R)File 135: NewsRx Weekly Reports
(c) 2008 NewsRx. All rights reserved.
0000230810 (THIS IS THE FULLTEXT)
Biotech company developing treatments based on adult stem cells
Biotech Business Week, July 18, 2005, p.399
DOCUMENT TYPE: Expanded Reporting LANGUAGE: English
RECORD TYPE: FULLTEXT
AUDIENCE: Consumer
Word Count: 1026
TEXT: As Congress spent hours passionately debating the merits
and ethics of embryonic stem cell research, nearly 50 Osiris
Therapeutics, Inc., employees of the company continued their work
on less controversial adult stem cells.
Thanks to U.S. Food and Drug Administration (FDA) fast-track
designation, Osiris expects to have an adult stem cell-based therapy
on the market by late 2007 to combat potentially fatal tissue
rejection among leukemia patients undergoing bone marrow transplants.
That's one of three adult stem cell-based therapies Osiris currently
has in human trials, to the delight of investors who muscled their
way into the company's latest funding round to raise $50 million,
more than double the expected amount.
Another human clinical trial squirts adult stem cells into
damaged knees after surgery to regrow meniscus, restoring the tissue
that acts as a shock absorber and preventing onset of arthritis.
The third experimental therapy being tested in humans - including
patients here at the Johns Hopkins University School of Medicine -
uses adult stem cells to help replace tissue damaged by heart attacks.
. . . .
|
